Leading the Future of Cancer Treatment with Intelligently Engineered iPSC NK Cells and Macrophages
Shoreline Biosciences is developing allogeneic, off-the-shelf, targeted, and standardized immunotherapies using intelligently engineered induced Pluripotent Stem Cell (iPSC)-derived NK cells and macrophages for serious diseases. Shoreline’s proprietary cell therapy platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced persistence and tumor killing. In addition, the company aims to restore tissue homeostasis and function by introducing engineered macrophages for fibrotic and inflammatory pathologies. Shoreline has developed expertise that we expect will allow for efficient and cost-effective manufacturing of these cells.
We are committed to scientific and clinical excellence and are passionate about bringing transformative therapies to patients in critical need.
Our Vision
To win the war on cancer through transformative cellular immunotherapies.
Our Mission
To change the lives of patients and their families living with cancer by developing safe, highly effective, and accessible allogeneic NK and macrophage cell therapies.
Leadership Team
Board Members
Science Advisory Board
Partnered with Advanced Cell Therapy Manufacturing
We are partnered with the Advanced Cell Therapy Laboratory (ACTL) of UC San Diego, a state-of-the-art GMP and GLP facilities that allows us to rapidly drive our innovation. We also leverage an extensive network of leading CMC professionals to guide our manufacturing agenda.